BerGenBio
Company

Last deal

$23.3M
Local Amount - NOK 250M

Amount

Post-IPO Debt

Stage

30.11.2023

Date

3

all rounds

$183.53M

Total amount

date founded

Financing round

General

About Company
BerGenBio is a biopharmaceutical company developing cancer treatments.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2007

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Debt

IPO status

Private

Description

BerGenBio focuses on developing selective AXL kinase inhibitors to treat aggressive cancers. They have raised $150.7M in funding and are listed under the ticker OSE:BGBIO. Using their proprietary technologies, such as CellSelect, they identify and validate novel drug targets and biomarkers. Their lead product, BGB324, is in clinical trials for acute myeloid leukemia and non-small cell lung cancer. They also work on discovering antibodies and small molecules to target AXL kinase. BerGenBio collaborates with other pharmaceutical companies to pursue therapeutic treatments for cancer and has a deep understanding of cancer biology, tumor micro-environment, and mechanisms of drug resistance.
Contacts
Similar Companies
1000
Aptose Biosciences

Aptose Biosciences

Aptose Biosciences is a biopharmaceutical company that develops novel anticancer therapies with high safety profiles.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Biopharma, Pharmaceuticals

Location

Toronto, ON, Canada

total rounds

9

total raised

$177.59M
Innate Pharma

Innate Pharma

Innate Pharma S.A. is a global biotech company that develops therapeutic antibodies to fight cancer by harnessing the immune system.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Marseille, France

total rounds

8

total raised

$314.54M
Inspirna, Inc.(formerly Rgenix, Inc.)

Inspirna, Inc.(formerly Rgenix, Inc.)

Inspirna is a biotechnology company that develops drugs to treat cancer.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

New York, NY, USA

total rounds

6

total raised

$139.5M
Epizyme

Epizyme

Epizyme is a biopharmaceutical company focused on developing treatments for blood cancer and tumors.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cambridge, MA, USA

total rounds

13

total raised

$794.08M

Financials

Funding Rounds
10
3

Number of Funding Rounds

$183.53M

Money Raised

Their latest funding was raised on 30.11.2023. Their latest round Post-IPO Debt

Date 
Funding Round 
Investors 
Money Raised 
Lead 
30.11.2023
$23.3M
Local Amount - NOK 250M
25.10.2022
1
$9.53M
Local Amount - NOK 100M
05.05.2020
$48.77M
Local Amount - NOK 500M

Meteva AS

Meteva AS

count Of Investments

2
Co-Investors
Investors
4
3

Number of lead investors

4

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Post-IPO Debt, Series D
Yes
Series A, Series B, Series C, Series D

Meteva AS

Meteva AS

count Of Investments

2
Sarsia Seed Management

Sarsia Seed Management

Norwegian VC firm Sarsia Seed Management invests in early-stage energy, cleantech, biotech, and life science companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

North Bergen, NJ, USA

count Of Investments

11

count Of Exists

1
Investinor

Investinor

Investinor is a Norwegian venture capital firm with $500m in assets.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Venture Capital, Finance

Location

Trondheim, Norway

count Of Investments

115

count Of Exists

13
Jon Oyvind Eriksen

Jon Oyvind Eriksen

Mr. Jon Eriksen is the Founder and serves as Chief Executive Officer at Aidiom. He served as a Board Member at Unacast. He serves as Chairman at Intelecy. He serves as Board Member at Loopfront. He serves as Industrial Advisor at Investinor. He also serves as a Board Member at Fonn. He founded and served as Chairman at Signicat. He is a serial entrepreneur with a proven track record of leading technology and media companies through start-up, growth, expansion, and exits, mergers, acquisitions, corporate spin-offs, and turnarounds. he has also held positions as chairman and member of the Board of Directors in several companies. He is currently a board member at Investinor's portfolio company BerGenBio AS and chairman of the board at Boost Communications AS. He served as a Board Member at Swarm64. He served as a Board Member at Novenda.

current job

Investinor
Investinor

organization founded

4
Ann-Tove Kongsnes

Ann-Tove Kongsnes

Ann-Tove Kongsnes holds an MSc in Economics and Business Administration from Bodø College (HiB) and the Advanced Program in Corporate Finance at the Norwegian School of Economics (NHH). She was previously an investment manager at ProVenture Managment AS, Business Development Manager at Leiv Eiriksson Nyskaping AS, Director of Marketing & Operations at NSEC Inc and Marketing Manager at the Norwegian Seafood Export Council. Mrs Kongsnes is a board member of Investinor’s portfolio companies Ayanda AS, Nordic Seafarms AS, poLight AS, Pharmalink AB, Soundrop AS and Gassecure AS. She is also deputy board member at BerGenBio AS and head of International Affairs at Investinor.

current job

EXACT THERAPEUTICS AS
EXACT THERAPEUTICS AS

People

Founders
2
David Micklem
David Micklem

David Micklem

current job

BerGenBio
BerGenBio

organization founded

1

David Micklem

James Lorens
James Lorens

James Lorens

organization founded

1

James Lorens

Employee Profiles
9
Cristina Oliva

Cristina Oliva

Chief Medical Officer

Martin Olin

Martin Olin

Chief Executive Officer

Richard Godfrey

Richard Godfrey

CEO

Brian McGuinness

Brian McGuinness

Strategic Consultant

Rune Skeie

Rune Skeie

CFO

David Micklem

David Micklem

Co-Founder, CTO ,Director of Biomarkers & Assay Development

Alan Barge

Alan Barge

Interim CMO

Anthony Brown

Anthony Brown

CSO

Activity

Recent News
12
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

week